Holen Sie sich die Stockscreener-App
3.52
3.30%
-0.12
Handel nachbörslich:
3.50
-0.02
-0.57%
Incannex Healthcare Inc Aktie (IXHL) Neueste Nachrichten
Incannex reactivates share repurchase program, cites ‘significant disconnect’ between its market cap and financial strength - MSN
IXHL Technical Analysis | Trend, Signals & Chart Patterns | INCANNEX HEALTHCARE INC (NASDAQ:IXHL) - ChartMill
Incannex Healthcare Commences DReAMzz Clinical Study for IHL-42X in OSA - Sleep Review
Incannex Healthcare Inc. 1Q 2026: Revenue $0.09M, EPS $(0.35) — 10-Q Summary - TradingView
IXHL: Cash rose to $74.5M, net loss reached $16.8M, and $9.1M was spent on share repurchases - TradingView
Incannex Healthcare (NASDAQ: IXHL) grows cash to $74.5M amid $16.8M loss - Stock Titan
Incannex Healthcare Commences DReAMzz Clinical Study Of IHL-42X For Obstructive Sleep Apnea - TradingView
Incannex launches DReAMzz study for sleep apnea treatment - Investing.com UK
Incannex Healthcare Launches DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea, Advancing Late-Stage Development 1 - Minichart
Incannex launches DReAMzz study for sleep apnea treatment By Investing.com - Investing.com South Africa
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea - The Manila Times
Incannex Healthcare Inc. Launches DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea Treatment - Quiver Quantitative
New sleep apnea drug enters dose-test in Incannex DReAMzz trial - Stock Titan
Incannex Launches DReAMzz Study for IHL-42X Sleep Apnea - TipRanks
Incannex Healthcare commences DReAMzz study for IHL-42X, 14 sites onboarded - TradingView
Incannex (IXHL) launches DReAMzz dose-optimization study of IHL-42X for sleep apnea - Stock Titan
IXHL Q3'26 Earnings: EPS estimate is (0.60) USD - TradingView
Incannex Wins MedTech Award for IHL-42X Sleep Therapy - TipRanks
Incannex Healthcare Wins MedTech Breakthrough Award for Innovative Obstructive Sleep Apnea Drug IHL-42X - Minichart
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development - The Manila Times
New oral sleep apnea drug IHL-42X wins global MedTech prize - Stock Titan
Incannex Healthcare wins MedTech Breakthrough award for IHL-42X after positive Phase 2 data - TradingView
Incannex (NASDAQ: IXHL) earns MedTech Breakthrough award for IHL-42X sleep apnea therapy - Stock Titan
TradingKey - TradingKey
Incannex Cannabis Gains Attention Across ASX 200 Healthcare Sector - Kalkine Media
Number of shareholders of Incannex Healthcare Inc. – NASDAQ:IXHL - TradingView
Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough - The Manila Times
Incannex Healthcare (IXHL) Expected to Announce Earnings on Thursday - MarketBeat
Incannex Healthcare wins award for innovative drug IHL-42X treating obstructive sleep apnea. - Pluang
Incannex Healthcare (NASDAQ:IXHL) Stock Price Up 2.8%Here's Why - MarketBeat
IXHL SEC FilingsIncannex Healthcare Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
2026's 10 Worst-Performing Stocks | Investing - U.S. News Money
Incannex says it holds $75 million in cash with zero debt after financing - MSN
$Incannex Healthcare (IXHL.US)$ - Moomoo
What Puts ASX 200 Incannex Cannabis Stocks in Focus? - Kalkine Media
IXHL Should I Buy - Intellectia AI
Incannex supports White House order on mental health treatments By Investing.com - Investing.com India
1.92%
4.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):